A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Pazopanib (Primary) ; Topotecan (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 13 Sep 2019 Status changed from active, no longer recruiting to completed.
- 03 May 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 23 Dec 2015 Status changed from recruiting to not yet recruiting as per ClinicalTrials.gov record.